DaVita (DVA)
(Delayed Data from NYSE)
$141.16 USD
-1.00 (-0.70%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $141.08 -0.08 (-0.06%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth C Momentum A VGM
Brokerage Reports
0 items in cart
DaVita Inc. [DVA]
Reports for Purchase
Showing records 161 - 180 ( 287 total )
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
Trimming Estimates on DMG Outlook and Commercial Mix Headwinds
Provider: KEYBANC CAPITAL MARKETS
Analyst: GURDA J
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
Trimming Estimates on Further DMG (formerly HCP) Weakness
Provider: KEYBANC CAPITAL MARKETS
Analyst: GURDA J
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
Capital Markets Day Highlights ESA Opportunity and Long Turnaround Time at DMG
Provider: KEYBANC CAPITAL MARKETS
Analyst: GURDA J
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
Raising Estimates on Better than Expected Kidney Care
Provider: KEYBANC CAPITAL MARKETS
Analyst: GURDA J
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
Light Guidance, but Growth Should Improve Beyond 2016
Provider: KEYBANC CAPITAL MARKETS
Analyst: GURDA J